Some people with lupus will develop a condition called Antiphospholipid Syndrome (APS). APS can lead to blood clots, and for pregnant women with lupus, pregnancy complications. We talk with Dr. Jane ...

APS is a systemic autoimmune disease associated with persistent antiphospholipid antibodies (aPL). It can cause thrombosis and pregnancy complications as well as non-thrombotic manifestations such as ...

Antiphospholipid syndrome (APS) is a systemic autoimmune disease in which antiphospholipid antibodies (aPL) increase the risk for thrombosis, pregnancy morbidity, and other nonthrombotic complications ...

Arterial thrombosis, venous thrombosis and morbidity during pregnancy, or a combination of these events, are clinical outcomes associated with antiphospholipid antibodies produced by patients with ...

Investigators from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) presented new research findings in antiphospholipid syndrome (APS) at the ...

Pathogenesis, treatment options and outcomes for antiphospholipid syndrome (APS) are poorly defined. A new observational collaborative study has analysed morbidity and mortality in APS, but, ...

Most clots seen in the antiphospholipid syndrome (APS) are venous; however, a proportion of clots can be arterial, leading to significant morbidity and mortality. Furthermore, arterial vascular ...

Antiphospholipid syndrome is an autoimmune disease that preferentially affects women. Patients with APS are typically given different medications to reduce their risk of blood clotting and help ...

U.S. Reps. Kat Cammack (R-Fla.-03) and Sydney Kamlager-Dove (D-Calif.-37) introduced a bipartisan resolution this month to expand prenatal screening for antiphospholipid syndrome, or APS, a treatable ...

Please provide your email address to receive an email when new articles are posted on . Preventing a first clotting event with aspirin may be the only truly effective treatment option in ...

Antiphospholipid syndrome occurred following treatment with pembrolizumab for unresectable, stage IIIB melanoma, according to a research letter. Despite the efficacy of anti-PD-1 agents for melanoma, ...

An international team of more than 80 collaborators led by Hospital for Special Surgery (HSS) investigators is developing new classification criteria for clinical research of antiphospholipid syndrome ...